HIV-2 Infection
8
1
2
4
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
12.5%
1 terminated out of 8 trials
80.0%
-6.5% vs benchmark
13%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients
Access HIV Ag/Ab Combo Assay - European Union (EU) Clinical Trial Protocol
Ex Vivo Characterization and Targeting of the Latent HIV Infected Reservoir to Cure HIV
A Prospective Cohort for ex Vivo Cure Studies With Chronic HIV Infected Patients in the Netherlands
RESIST-2: 2nd-line ART for HIV-2 Infection
Cohorte Nationale VIH-2
First-Line Treatment for HIV-2
An Open Label Trial of Stribild for Antiretroviral (ARV)-naïve HIV-2 Infected Adults in Dakar, Senegal